Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1

Oncogene

Volumn 33, Issue 4, 2014, Pages 514-524

  Wang, P ^a,b   Chen, L ^a,b   Zhang, J ^a,b   Chen, H ^a,b   Fan, J ^c   Wang, K ^a,b   Luo, J ^a   Chen, Z ^a,b   Meng, Z ^a,b   Liu, L ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Methylation; miR 124; Pancreatic cancer; Prognosis; Rac1

Indexed keywords

MICRORNA 124; MICRORNA 124 1; MICRORNA 124 2; MICRORNA 124 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; MICRORNA; MIRN124 MICRORNA, HUMAN; RAC1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME INACTIVATION; EPIGENETICS; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PYROSEQUENCING; RNA METHYLATION; SURVIVAL TIME; ANIMAL; CELL MOTION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RAC1 GTP-BINDING PROTEIN; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84897018932     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.598     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057.
3. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68: 801-808.
4. Ouyang H, Wang P, Meng Z, Chen Z, Yu E, Jin H et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011; 40: 120-125.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
6. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10: 126-139.
7. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856.
8. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18: 534-545.
9. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48-57.
10. Li X, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a sevenmicroRNA signature. Gut 2009; 59: 579-585.
11. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
12. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
13. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429.
14. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011; 32: 1183-1189.
15. Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem 2010; 56: 1107-1118.
16. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9: 293-301.
17. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
18. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776.
19. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2011; 61: 278-289.
20. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010; 9: 167.
21. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol 2003; 3: 235-240.
22. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38: 1378-1385.
23. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997; 390: 632-636.
24. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005; 24: 7821-7829.
25. Grijelmo C, Rodrigue C, Svrcek M, Bruyneel E, Hendrix A, de Wever O et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNKdependent signaling pathways in colon cancer cells. Cell Signal 2007; 19: 1722-1732.
26. Kanwal R, Gupta S. Epigenetics and cancer. J Appl Physiol 2012; 109: 598-605.
27. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2011; 61: 33-42.
28. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552-3562.
29. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011; 17: 4965-4974.
30. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009; 124: 2367-2374.
31. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 56-61.
32. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995; 374: 457-459.
33. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci 2011; 17: 2561-2571.
34. Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011; 141: 730 e711-717.
35. Medina PP, Slack FJ. Inhibiting microRNA function in vivo. Nat Methods 2009; 6: 37-38.
36. Mardin WA, Mees ST. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol 2009; 16: 3183-3189.
37. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
38. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908.
39. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298-311.
40. Lekanne Deprez RH, Fijnvandraat AC, Ruijter JM, Moorman AF. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem 2002; 307: 63-69.
41. Wang P, Chen Z, Meng ZQ, Fan J, Luo JM, Liang W et al. Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function. Carcinogenesis 2009; 30: 1497-1506.
42. Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM. Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett 2009; 283: 84-91.
43. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T et al. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst 2005; 97: 1734-1746.
44. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.
45. Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 2010; 120: 1178-1191.
46. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD. A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc 2009; 4: 107-115.
47. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 2010; 31: 1726-1733.